I undersøgelsen af stoffets evne til at øge antallet af røde blodlegemer var hæmoglobinniveauet cirka 11, 6 g/ dl gennem de sidste fire uger af undersøgelsen i forhold til cirka 8, 0 g/ dl inden behandlingens start.
In the correction study, haemoglobin levels were around 11.6 g/ dl during the last four weeks of the study, having risen from around 8.0 g/ dl before treatment.